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ABSTRACT: Amyloidogenesis is significant in both protein function and pathology. Amyloid formation of folded, globular proteins is 
commonly initiated by partial or complete unfolding. However, how this unfolding event is triggered for proteins that are otherwise stable in 
their native environments is not well understood. The accumulation of the immunoglobulin protein β2-microglobulin (β2m) into amyloid 
plaques in the joints of long-term hemodialysis patients is the hallmark of Dialysis Related Amyloidosis (DRA). While β2m does not form 
amyloid unassisted near neutral pH in vitro, the localization of β2m deposits to joint spaces suggests a role for the local extracellular matrix 
(ECM) proteins, specifically collagens, in promoting amyloid formation. Indeed, collagen and other ECM components have been observed to 
facilitate β2m amyloid formation, but the large size and anisotropy of the complex, combined with the low affinity of these interactions, has 
limited atomic-level elucidation of the amyloid-promoting mechanism(s) by these molecules. Using solution NMR approaches that uniquely 
probe weak interactions in large molecular weight complexes, we are able to map the binding interfaces on β2m for collagen I and detect 
collagen I-induced µs–ms timescale dynamics in the β2m backbone. By combining solution NMR relaxation methods and 
15
N-dark state 
exchange saturation transfer experiments, we propose a model in which weak, multimodal collagen I–β2m interactions promote exchange 
with a minor population of amyloid-competent species to induce fibrillogenesis. The results portray the intimate role of the environment in 
switching an innocuous protein into an amyloid-competent state, rationalizing the localization of amyloid deposits in DRA. 
INTRODUCTION 
Several proteins self-associate into amyloid fibrils, which in some cases have functional roles
1-3
, but for others are associated with 
debilitating human diseases
4-6
 including Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, type II diabetes, cataracts, and 
Dialysis Related Amyloidosis (DRA). The protein precursors of amyloid diseases have unrelated primary sequences and structures
7
, spanning 
natively unfolded (intrinsically disordered) states, such as α-synuclein, amyloid-β peptide, and tau
8-10
, to stable, globular proteins, such as β2-
microglobulin (β2m), transthyretin, and immunoglobulin light chains
11-13
. Initiation of amyloid formation of the latter class of proteins 
requires complete or partial unfolding of monomeric precursors, which can transiently assume amyloid-competent state(s). This kinetic 
barrier may be lower for intrinsically disordered proteins. However, what triggers the initial unfolding and subsequent amyloidogenesis of 
natively folded globular proteins remains poorly understood.  
Accumulation of β2m amyloid plaques in the joints of long-term hemodialysis patients leads to DRA and arthritic symptoms
14-17
. In healthy 
individuals, β2m dissociates from the major histocompatibility complex-I (MHC-I), is released into the plasma, and is carried to the kidneys 
for degradation
18-19
. However, when hemodialysis or peritoneal dialysis are required due to kidney failure, β2m is not efficiently removed 
from the plasma, leading to increased concentrations of the protein by up to 60-fold
16, 20-21
. Remarkably, despite being transported throughout 
the body, β2m accumulates into amyloid plaques specifically in skeletal tissues of dialysis patients
16, 21-24
. The mechanism(s) by which β2m 
fibrillizes in vivo is not well understood, since in isolation the wild-type protein (the major culprit of DRA) resists amyloid formation in vitro 
under physiological conditions, even at high (100 µM) concentrations
25-26
. It has been proposed that β2m amyloid localized in the joints could 
result, at least in part, from interactions with the major components of the extracellular matrix (ECM) in bone and cartilage: collagens I and 
II
20-23
 and glycosaminoglycans (GAGs)
27-29
. The binding affinities of β2m to these collagens have been shown to be in the µM–mM range
30
, 
with preference for collagen I
27
. Although the interaction is weak, it is nonetheless pathologically significant, as images of ex vivo DRA 
plaques reveal β2m amyloid covering the surface of collagen I fibrils
21





, as well as pre-formed fibril seeds and other co-factors
25-26, 28, 31-49
, induce and modulate β2m 
amyloid formation. However, atomic details of how these components interact with, and induce, amyloid formation of β2m have remained an 
open question. 
The weak nature of the interaction and large, anisotropic shape of the β2m–collagen I complex, create a challenge for deriving atomic-level 
information on how collagen I–β2m interactions initiate β2m amyloidogenesis. The immunoglobulin fold of monomeric β2m has dimensions 
of ~ 4 nm x 2 nm x 2 nm, whereas the simplest triple helical unit of collagen I has strikingly larger dimensions of 300 nm x 1.5 nm x 1.5 nm. 
Collagen I triple helices assemble into even larger, structured fibrils that have diameters ranging from 10–500 nm and lengths on the µm-
2	
	
scale. Collagen I therefore presents as a large surface with numerous reactive groups for β2m interactions. These challenges are not 
insurmountable, however, as powerful solution nuclear magnetic resonance (NMR) spectroscopy methods can indirectly probe large, lowly 
populated complexes in site-specific detail that are invisible by other biophysical techniques.  
In this study, by utilizing NMR spectroscopy experiments designed to probe large complexes, we are able to pinpoint the binding interfaces 
of wild-type β2m for collagen I at physiological pH and have shown the interfaces to involve both β-sheets of the native protein, suggestive of 
different binding modes between these two proteins. Residues identified at the binding interface include both hydrophobic and hydrophilic 
sidechains. Through 
15
N relaxation experiments, we have also found that collagen I increases the number of residues in β2m involved in 
conformational exchange on the µs–ms timescale. These regions include residues 6–11 (β-strand A), 36–39 (β-strand C), 51 (β-strand D), and 
91–94 (β-strand G) in the edge β-strands and loop residues 15–20 (loop AB), 35 (loop BC), 52-53 (loop DE), 63 (loop DE), and 78 (loop EF), 
the dynamics and conformations of which are known to be important for β2m amyloid formation
31, 38, 50-51
. We propose that the weak 
interactions of collagen I with the β2m β-sheets and loops promote exchange of the native protein with minor populations of more amyloid-
competent species that induce fibrillogenesis. This study illuminates how a protein component, collagen I, local to the environment in which 
β2m plaques are found, can interact with a stable, globular protein to initiate debilitating amyloid formation.  
 
RESULTS  
Collagen I induces β2m amyloid formation in a concentration-dependent manner.  
Since the direct interaction of β2m with collagen in the joint space has been proposed to induce β2m amyloid formation
21, 27
, we probed the 
β2m–collagen I interaction under physiological pH conditions (pH 7.4) using solid-phase enzyme-linked immunosorbent assays (ELISA) 
(Figure 1A, S1). This is a colorimetric assay that detects an HRP-conjugated anti-β2m primary antibody and indicates the presence of β2m 
bound to collagen I immobilized in a 96 well plate. Importantly, the results suggest a dose-dependent interaction of the two proteins, 
consistent with previously published results
27
, under the conditions employed here. We observe that the β2m–collagen I binding does not 
easily saturate with increasing concentrations of β2m (up to 100 µM; Figure S1), consistent with the low affinity of the interaction at pH 7.4 
(Kd ≈ 410 µM
30
) measured previously by surface plasmon resonance. The adhesion of β2m to casein was monitored as a negative control, for 
which no significant binding was observed (Figure 1A).  
Having verified the β2m–collagen I interaction under physiological pH conditions, we next monitored amyloid growth of β2m in the 
presence or absence of collagen I by thioflavin T (ThT) fluorescence (Figure 1B). In the presence of 3.4 mg/ml collagen I (1:0.1 molar ratio 
β2m:collagen I), β2m amyloid is formed within 400–600 hrs at pH 7.4 (Figure 1B, blue), as evident by enhanced ThT fluorescence. This is not 
observed in the absence of collagen I in the same conditions, and collagen I alone does not show ThT fluorescence enhancement (Figure 1B). 
Notably, at lower concentrations of collagen I, lower β2m concentrations, or shorter timescales, fibrils are not observed
29, 31
. Collagen I-
induced β2m amyloid formation is accelerated at pH 6.2 relative to at pH 7.4 (Figure S2A–B), enabling measurement of the dependence of 
the rate of fibril formation on the concentration of collagen I. The results showed that at this pH β2m amyloid formation is dependent on 
collagen I concentration, as addition of 3.4 mg/ml collagen I significantly reduces the lag time and half time of β2m aggregation relative to 
0.34 mg/ml or 0.17 mg/ml collagen I (Figure S2C–D). This trend is consistent with our previously published data
29
, in which increasing 
concentrations of collagen I (0–0.47 mg/ml) accelerated β2m amyloid formation at pH 6.2 in the presence of a constant concentration of the 
glycosaminoglycan, heparin. These results reinforce earlier proposals that collagen I–β2m interactions play a significant role in triggering β2m 
fibril formation
21
. Atomic force microscopy (AFM) images also showed that β2m interacts with collagen I fibrils, consistent with previous 
results
21
, showing that β2m coats the collagen I fibril surface before detectable fibril formation occurs (monitored by ThT fluorescence), 
obscuring the characteristic collagen I fibril D-banding that is clearly observed in the absence of β2m (Figure 1C,D). Importantly, control 
experiments showed that β2m alone (Figure 1E) does not aggregate in the conditions employed, with no fibrils or high molecular weight 
assemblies observed by AFM. Together, these data confirm that adhesion of collagen I and β2m induces amyloid formation under 




Figure 1. Detection of collagen I-driven β2m amyloid formation. (A) ELISA probing dose-dependent adhesion of β2m (10–80 µg/ml) to collagen I 
(10 µg/ml) or casein (10 µg/ml, used as a negative control), at pH 7.4. The average absorbance at 450 nm from triplicates within the same plate are 
reported with the standard deviation given as error bars. (B) ThT fluorescence curves of 85 µM β2m (black), 85 µM β2m + 3.4 mg/ml (8.5 µM) 
collagen I (blue), or 3.4 mg/ml collagen I alone (orange) over 650 hrs in 10 mM sodium phosphate buffer, pH 7.4, shaking at 600 rpm at 37°C. Three 
representative curves are given for each condition. The insert shows a zoom-in of the baseline of the ThT fluorescence curves to highlight the lack of 
fluorescence enhancement for both β2m (black) and collagen I (orange) alone. (C–E) Representative amplitude-modulated AFM images of (C) β2m 
co-incubated with collagen I fibrils, (D) collagen I fibrils alone, and (E) β2m alone after incubation for 96 hrs at 37°C with shaking. 
 
Weak, but specific β2m–collagen I interactions observed through 
15
N-R2 perturbations. 
In order to understand the mechanistic details by which collagen I interacts with β2m and initiates amyloid formation, we used solution 
NMR methods, which provide an excellent toolbox of approaches able to characterize residue-specific features of weak protein–protein 
interactions on multiple timescales
52-55





N heteronuclear single quantum correlation (HSQC) spectra (Figure S3). However, a residue-specific attenuation of the 
peak intensities was observed with increasing collagen I concentrations (Figure 2A), suggesting specific, although weak β2m–collagen I 
interactions. To minimize collagen I aggregation during the NMR experiments and to capture the most specific interactions, we proceeded 
with low collagen I concentrations (0.6–1.2 mg/ml) that displayed consistent residue-specific perturbations and kept samples at 10°C, 
allowing NMR spectra to be acquired for over one week without visible alterations in spectral quality. Under these conditions addition of 1.2 
mg/ml collagen I to 300 µM β2m resulted in a reduction in resonance intensity of all peaks, consistent with transient formation of a high 
molecular weight complex (Figure 2A). However, the greatest reduction in peak intensities occurred for residues in the eight β-strands of the 
wild-type protein (Figure 2A). These peak intensity losses arise, in part, from increased 
15
N-transverse relaxation rates (R2), which are 
sensitive to changes in internal motions on the ps–ns timescale and conformational exchange on the µs–ms timescale. Indeed, at these 
concentrations we observe an overall increase in 
15
N-R2 values of β2m relative to their magnitude in the absence of collagen I, but 
importantly, the increase is not uniform across all residues, but is residue specific, involving predominantly residues 2–3 (N-terminus), 7–11 
(β-strand A), 16–19 (loop AB), 23–26 (β-strand B), 35–39 (β-strand C), 50–52 (β-strand D), 64, 66–69 (β-strand E), 79–82 (β-strand F), 85, 
87 (loop FG), and 91–94 (C-terminal β-strand G) (Figure 2B-C). The increased 
15
N-R2 at these specific sites could have multiple origins, 
arising from reduced backbone mobility upon direct interaction with collagen I and/or to line broadening due to exchange between species 
with different chemical shifts, especially since the observed 
15
N-ΔR2 is dependent on magnetic field (700 MHz vs. 900 MHz, Fig. S4). In 
order to disentangle these contributions to the increase in 
15
N-R2, we proceeded with two sets of NMR experiments: 
15
N-dark state exchange 
saturation transfer (DEST) experiments, which can identify residues in β2m interacting with the large collagen I fibrils, and in-phase Hahn-





Pinpointing the collagen I interaction interface on β2m through 
15
N-DEST. 




. This experiment 
is optimal when there is a measurable increase in R2 due to formation of a transient, large molecular weight complex that is NMR-invisible 
because of its high R2 and detects the exchange between an observable ‘light’ state (free monomeric β2m) and the NMR-invisible ‘dark’ state 
(the high molecular weight collagen I–β2m complex). In the DEST experiment, resonances of high molecular weight species with high R2 
values, such as the collagen I–β2m complex, can be partially saturated by weak radiofrequency (RF) fields at frequency offsets far from 
monomeric β2m resonances. Saturation transfer to the observable monomeric species by chemical exchange is detected as a loss in 
monomeric β2m signal intensity. The broadening of these DEST saturation profiles (reduced signal intensities at further frequency offsets) in 
the presence of collagen I, relative to in its absence, is therefore indicative of residues at the interaction interface (Figure 3A–B). The 
‘broadness’ of the profiles was measured by calculating the DEST difference (Θ) for each residue, which is a measure of the relative effects 
of on-resonance and off-resonance 
15




, where ±30 kHz were the most off-resonance 
15
N offsets, and 
15
N offsets of ±4 kHz provide enough 
saturation transfer from bound to unbound β2m to show significant intensity loss without eliminating the signal in most cases. Notably, we 
observe that the broadening of the DEST saturation profiles is residue-specific and not uniform across all β2m residues, with some residues 
showing no change in the DEST difference in the presence of collagen I (Figure 3A–B). Examples of DEST profiles in the presence or 
absence of collagen I for a residue that shows DEST due to collagen I binding (V82 in β-strand F) and one that does not (K41 in the C–C’ 
loop) are given in Figure 3B. In Figure 3A, those residues with ΔΘ larger than the mean, and likely have the most direct contacts with the 
collagen in the β2m–collagen I complex (shaded red), include residues 6–11 (β-strand A), 15–20 (loop AB), 21–26 (β-strand B), 35 (loop 
BC), 36–39 (β-strand C), 51 (β-strand D), 52–53 (loop DE), 63 (loop DE), 64–69 (β-strand E), 78 (loop EF), 79–83 (β-strand F), and 91–94 
(β-strand G).  
 
 
In addition, the full DEST profiles can be used to quantify residue-specific transverse relaxation values of β2m in the collagen I-bound state 
Figure 2. Characterizing residue-specific β2m–collagen I binding through 
15





N HSQC spectra of 300 µM β2m in the presence of 1.2 mg/ml collagen I compared with values in the absence of collagen I (gray bars). 
The dashed line is drawn at the average signal intensity ratio over the entire protein. Dips in the signal intensity reflect regions maximally perturbed 
by the presence of collagen I. Error bars are propagated from the noise level of the spectra. The secondary structural elements of β2m are indicated 
above the plot. (B) 
15
N-R2 measurements of 300 µM β2m in the presence (red) or absence (black) of 1.2 mg/ml collagen I. The errors are propagated 
from the fitting errors. The dashed lines indicate the mean 
15
N-R2 values of β2m in the presence or absence of 1.2 mg/ml collagen I over the entire 
protein. All experiments were conducted in TBS, pH 7.4 containing 0.5 mg/ml casein as a non-specific binding blocking agent at 10°C. Note that in 




N HSQC spectrum due to inherent 
conformational exchange, consistent with previous results
49
. (C) Solution NMR structure of the WT-β2m monomer (PDB: 2XKS
49
) highlighting 
residues that show an increase in 
15
N-R2 higher than 13.4 s
-1
 (the mean Δ
15
N-R2) upon addition of 1.2 mg/ml collagen I.  
Figure 3. 
15
N-DEST to identify collagen-binding interface on 
15
N-β2m. (A) ΔΘ calculated from 
15
N-β2m DEST intensities at ±30 kHz and ±4kHz 
15
N offsets with a 350 Hz saturation frequency in the presence or absence of collagen I (gray bars). The secondary structure is shown above the plot. 
(B) Examples of 
15
N-DEST profiles of 300 µM 
15
N-β2m in the presence (solid line, solid circles) or absence (dashed line, open circles) of 0.6 mg/ml 





 for each residue determined from fitting 
15
N-DEST profiles to the McConnell equations. (D) Examples of fit DEST profiles using the same 
residues as in (B). Data points are shown as circles and the fits as solid lines (gray- 150 Hz saturation, black- 350 Hz saturation). All experiments 
were carried out in TBS, pH 7.4, 10°C at 700 MHz 
1





) and exchange kinetics between the bound and unbound β2m. Since the ΔR2 may be due to more complex processes than collagen I 
binding alone, such as an overall increased viscosity due to the presence of the large collagen I molecules, we fit only the 
15
N DEST profiles 
of each residue with 150 Hz and 350 Hz RF saturation to the McConnell equations
56-57
. The use of two RF fields provides an additional 
constraint to distinguish between models with equal fits to data acquired at only one RF field and provides more accurate determination of 
kinetic parameters
57
. Fitting to a simple two-state model, the population of the unbound, monomeric β2m was determined to be 94 +/- 2% 
with an apparent first-order rate constant for the conversion of β2m from unbound to collagen I-bound conformation (kon
app
) of 6.4 +/- 0.8 s
-1
. 






 profile shows a similar trend to the ΔΘ 
profile (Figure 3A, C), and suggests that binding interfaces for collagen I on β2m occur on both β-sheets. Examples of fitting to the 
experimental values of residues V82 (in a binding region) and K41 (away from interface) are shown in Figure 3D.  
 
Collagen I induced conformational exchange in β2m revealed by 
15
N relaxation. 
The enhanced observed 
15
N-R2 of β2m may not only be due to the increased intrinsic 
15
N-R2 caused by slowed molecular motions upon 
binding with a high molecular weight species (such as in a large complex), but also to an increased contribution of chemical exchange 
dynamics on the µs–ms timescale, since the 
15
N-ΔR2 is dependent on the magnetic field (Figure S4). Chemical exchange describes the 
interconversion of a residue between multiple states with distinct chemical shifts, such as in the case of conformational conversion or 
complex formation. In order to qualitatively determine which residues in β2m are in conformational exchange in the presence of collagen I, 
we use 
15
N in-phase Hahn echo experiments (R2
HE
) to estimate the chemical exchange contribution to the observed 
15
N-R2, denoted Rex. An 
increase in Rex in the presence of collagen I, relative to in its absence, suggests collagen I-induced conformational exchange on a per residue 
basis. At pH 7.4 and 10°C, few residues in β2m have Rex values greater than 10 s
-1 
in the absence of collagen I as measured by the in-phase 
Hahn echo experiments (Figure 4A). In the absence of collagen I, the N-terminal seven amino acids and residues in the BC and DE loops (for 
which several signals are unobservable) are inherently in conformational exchange (Figure 4A). Upon addition of 0.6 mg/ml collagen I, the 
regions with high Rex are expanded to include the N-terminus and full β-strand A, part of β-strand B to part of β-strand C, including the 
connecting BC loop, β-strand D, the DE loop, the C-terminal residue of β-strand F into the FG loop, and the C-terminal β-strand G (Figure 
4B). Conformational dynamics in specific regions of β2m, including the N-terminal region, edge β-strands C and D, and the BC loop that 
contains cis Pro32, have been shown previously to be crucial in controlling the amyloidogenicity of the protein
49, 58-60
. Thus, the enhanced 




A novel collagen I binding surface on β2m. 
Amyloid formation of β2m at physiological pH in vitro requires assistance by co-factors
21, 25-26, 28-29, 31-49
. In particular, ECM molecules, such 
as collagens and GAGs have been targeted as amyloid-inducing co-factors, since β2m amyloid formation is localized to musculoskeletal 
tissues
16, 22-24
. While previous experiments have focused on the kinetics of amyloid formation in the presence of these molecules
21, 28-29, 31, 61
, a 
detailed atomistic description of the interactions involved and how these may enhance β2m conformational dynamics and amyloid formation 
had not been elucidated. Here, we have used complementary NMR relaxation-based experiments to pinpoint residues of β2m involved in the 
collagen I binding interface and collagen I-induced dynamics that lead to enhanced β2m amyloid formation at neutral pH in vitro. The 
15
N-
Figure 4. Conformational exchange in β2m induced by collagen I. Relaxation exchange rates (Rex) obtained by 
15
N-R2 Hahn echo experiments for 
each residue in 300 µM 
15
N-β2m in the absence (A) or presence (B) of 0.6 mg/ml collagen I at pH 7.4, 10°C, 700 MHz 
1
H Larmor frequency. Rex 
values over 10 s
-1
 are indicated in blue bars. Regions shaded in cyan in both panels contain several residues with Rex >10 s
-1
 in the respective 
conditions. Residues with unobservable cross-peaks in the absence of collagen I are indicated by open circles. Residues that are observable in the 
absence of collagen I, but are reduced to the level of the noise in the presence of collagen I are indicated by filled blue circles. Error bars are 
propagated from fitting errors.  
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DEST experiments indicate that residues in β-strands A, B, C, D, E, F, and G form interaction surfaces with collagen I. These provide two 
surfaces of mixed hydrophilic and hydrophobic composition (Fig. S5). Both contain hydrophobic patches, with the ABED β-sheet displaying 
several aromatic residues on the interaction surface (Fig. S5). Since both β-sheets on opposite sides of β2m were shown to interact with the 
collagen I surface, binding must be multimodal involving interaction surfaces formed by K6, Q8, Y10, F22, N24, Y26, S52, Y63, L65, Y67, 
and E69 on the ABED β-sheet and E36, D38, L40, A79, R81, N83, I92, and K94 on the GFC β-sheet (Figure 3, S5). Comparison of the 
molecular dimensions of the interacting molecules (4 nm x 2 nm x 2 nm for β2m, 300 nm x 1.5 nm for a collagen I triple helix, and microns in 
length and up to 500 nm in diameter for mature collagen I fibrils) highlights the potential for a myriad of binding modes, enabling 
independent binding of several β2m molecules to the same collagen molecule (Figure 5A–B). Importantly, the collagen I triple helix surface 
is interspersed with numerous hydrophilic and hydrophobic residues along its length (Figure 5A). The collagen I fibril surface maintains this 
repeating pattern of surface chemistries (Figure 5B), enhancing the potential for multiple binding modes to complementary surfaces on β2m 
(Figure 5C). 
 
Figure 5. Potential surface contacts for β2m–collagen I interaction. (A) Surface model of the collagen I monomer (PDB: 3HR2
62
) color-coded by 
amino acid type (top: hydrophilic, bottom: hydrophobic). A surface representation of β2m is shown for size comparison (PDB: 2XKS
49
). As an 
example, electrostatic surfaces of β2m are shown weakly interacting with electrostatic surfaces of collagen I. (B) Surface models of the collagen I 
fibril repeating unit (built from PDB: 3HR2
62
), color-coded by amino acid type (top: hydrophilic, bottom: hydrophobic). The repeating unit is ~67 nm 
in length, however mature fibrils can be microns long and ~500 nm in diameter. Distinct bands of electrostatic residues are observed within the 
repeating unit. (C) Surface representation of β2m monomer (PDB: 2XKS
49
) color-coded by amino acid type (left: hydrophilic, right: hydrophobic). 
All models are color-coded as: red, acidic; blue, basic; purple, uncharged-polar; and green, hydrophobic.  
	
Collagen I is known to interact with multiple immunoglobulin-like protein folds through binding interfaces that include both hydrophobic 
and hydrophilic residues. Interactions of collagen I with osteoclast-associated receptor (OSCAR), leukocyte-associated immunoglobulin-like 
receptor-1 (LAIR-1), and glycoprotein VI (GPVI), play functional roles in immune system regulation
63-66
 and platelet activation
67-69
. Similar 
to the β-sheet binding interface on β2m for collagen I identified here, the collagen I binding sites on OSCAR and LAIR-1 are also found in β-
sheet regions
70-71
. In the case of the OSCAR–collagen I interactions, Tyr and Arg residues that line the interacting β-sheet of OSCAR have 
been suggested to play a primary role
70
. LAIR-1 binds primarily to collagen fragments rich in Gly, Pro and hydroxyproline (GPO) content, 
but also has been shown to interact with multiple binding motifs in collagen II and III toolkit peptides, some of which are not GPO rich
71
. 
NMR and mutagenesis studies on LAIR-1 have shown that depletion of Arg or Glu at the putative β-sheet interface showed decreased 
collagen binding, suggesting a role for electrostatic interactions
72
. GPVI, also recognizes GPO rich collagen motifs, however through a 
unique hydrophobic groove formed by a β-strand connecting loop that is flanked by hydrophilic residues
73-75
. Thus, although these proteins 
all share a similar immunoglobulin fold, each shows a unique binding interface to collagen, interacting in grooves formed by β-sheets or 
loops and having both hydrophobic and hydrophilic residues that each plays fundamental roles in binding.  
 
Collagen-induced conformational dynamics in β2m reflect amyloid prone dynamics. 
Beyond the structured collagen I-binding interface of β2m, using 
15
N relaxation experiments, we observe enhanced dynamics in the N- and 
C- terminal regions, the BC and FG loops, and the β-strand D of β2m upon complex formation. Enhanced dynamics in each of these regions 
has been proposed to play key roles in the aggregation mechanism of wild-type β2m
38, 49-51, 59-60, 76-86
. Amyloid formation of β2m is nucleation 
dependent and proceeds through a near native folding intermediate, IT, that is in part defined by a non-native trans-His31-Pro32 peptide bond 
in the BC loop
38, 50-51, 87-88
. NMR studies of a P32G-β2m variant, which inherently has a trans-His31-Gly32 peptide bond, showed significant 
line broadening in β-strands A and D and the BC and FG loops relative to WT-β2m
38
. This was interpreted to result from conformational 
7	
	
conversion between the native and IT conformations
38
. The observation of increased Rex of these same regions upon addition of collagen I to 
WT-β2m in this study, is consistent with the same regions undergoing conformational exchange from the native state to enhance the 
formation of non-native species with enhanced amyloid potential.  
The cis-trans isomerization of Pro32 is aided by displacement of the N-terminal six residues, as in the naturally occurring amyloidogenic 
variant, ΔN6
49, 76, 89-90
, which destabilizes the protein, allowing β2m to sample multiple amyloidogenic conformations that enhance the rate of 
aggregation
38, 50-51, 76, 81-83, 87-88
. In addition, NMR relaxation experiments show enhanced dynamics in β-strand D and the BC and DE loops of 
amyloidogenic ΔN6, which have been proposed to contribute to its higher aggregation propensity
49
. Consistent with this, collagen I-induced 
enhancement of conformational exchange in the BC and DE loops of WT-β2m in this work may rationalize the increased β2m 
amyloidogenicity in the presence of collagen I. 
Another proposed mechanism of the initiation of aggregation of WT-β2m involves destabilization of the edge β-strands A, D, C, and G to 
expose the β-strands with the highest aggregation propensity, namely β-strands B and E, unleashing their amyloid potential. Protection of the 
aggregation-prone β-strands was suggested to play a role in the amyloidogenicity of pathological variant D76N-β2m, which rapidly self-
assembles into amyloid fibrils at neutral pH in vitro in the absence of co-factors
59
, and an aggregation-resistant variant, W60G-β2m
60
. Indeed, 
a recent study on D76N-β2m proposed that the enhanced aggregation propensity of this protein arises, in part, due to destabilization of the 
edge strands and conformational exchange in β-strand A, the BC loop, and the EF loop
59
. In line with this hypothesis, reduced aggregation 
propensity of W60G-β2m, relative to WT-β2m, has been suggested to result from increased protection of the solvent exposed residues in the 
aggregation-prone β-strands, along with reduced dynamics of the protein, including in edge β-strands and the aggregation-prone β-strand B
60
. 
Analogously, we find that collagen I enhances conformational exchange in the edge β-strands, A, D, C, and G, which may allow increased 
sampling of alternative conformations in these strands, deprotecting the aggregation-prone β-strands B and E, to enhance amyloidogenicity.  
 
A proposed mechanism of collagen I-driven β2m amyloidogenesis. 
With the new insights into the binding interface of collagen I on β2m and its impact on β2m dynamics described here, we propose a 
mechanistic view by which collagen I might drive amyloidogenesis of β2m (Figure 6). In the presence of collagen I, the β-sheets of β2m are 
available for binding to the collagen I surface, with both β-sheets providing potential binding interfaces, indicative of multiple binding 
modes, rather than a unique and specific binding interface. Through modification of the dynamics of β2m in the BC loop and the edge strand 
regions, concomitant sampling of amyloid-competent species, including the IT state
87-88
, may be increased by a heightened probability of cis-
trans isomerization of Pro32
38, 50-51
 and/or exposure of highly amyloidogenic B and E β-strands enabling them to realize their amyloid 
potential. Binding to collagen I may also concentrate bound β2m molecules, enhancing the probability of self-association, or may increase the 
potential for secondary nucleation on the collagen I surface, enhancing fibril formation. All, or several, of these mechanisms may be at play 
to catalyze β2m aggregation both in vitro and provide a molecular rationale for the deposition of β2m in collagenous-rich joints in dialysis 
patients
16, 21-24
. More generally, they also serve as an exemplar of the key role of the physiological environment in amyloid formation, by 
rationalizing the often remarkably specific deposition of amyloid to different tissues
1
, and in some cases, of different variants of the same 
protein in different tissues
91-92
. The methods used here to interrogate the weak-transient interaction of the large, β2m–collagen I complex can 
be extended to future studies to gain atomic-level insight into how other physiologically relevant cofactors promote amyloid formation of 
globular proteins involved in other amyloid diseases.  
 
Figure 6. Proposed mechanism for collagen-driven β2m amyloidogenesis. Alone, the β2m monomer (PDB: 2XKS
49
) does not readily aggregate 
into amyloid fibrils. Upon addition of collagen I, we have observed interaction interfaces to include both β-sheets of β2m through the 
15
N-DEST 
experiment (red). Collagen also induces conformational exchange in regions colored in blue, as assessed by 
15
N relaxation experiments. The 
interaction of collagen I with the structured regions of β2m enhances conformational exchange, promoting formation of amyloid-competent species 




MAT ERIALS AND METHODS 
Expression and purification of β2m. 
Wild-type β2m was expressed recombinantly in Escherichia coli BL21(DE3) pLysS cells by induction with 1 mM IPTG overnight at 37°C, 
following methods described previously
39
. Cells were lysed in 25 mM Tris-HCl buffer, pH 8.0 and with an Avestin Emulsiflex-C5 
homogenizer. β2m is accumulated in inclusion bodies. To extract the β2m from inclusion bodies, the cell pellet was washed five times with 25 
mM Tris-HCl buffer, pH 8.0 and solubilized in 25 mM Tris-HCl, pH 8.0 buffer containing 8 M urea, rocking overnight at room temperature. 
The protein was verified to be in the soluble fraction by SDS-PAGE. β2m was refolded by dialyzing against 25 mM Tris-HCl buffer, pH 8.0 
at 4°C and purifying by anion exchange (HiTrap Q HP, GE Healthcare). The protein was further purified by size exclusion chromatography 
with a HiLoad 26/600 Superdex 75 gel filtration column (GE Life Sciences). Protein purity was verified by SDS-PAGE, and concentrations 












Relative adhesion of variable concentrations of β2m to collagen I was determined by ELISA experiments. Nunc Maxisorp 96-well plates 
(Thermo Scientific) were coated with 100 µl of collagen I from rat tail tendon (BD Biosciences; 10 µg/ml in 10 mM acetic acid) overnight at 
4°C. Uncoated areas on the plates were blocked with 200 µl of 0.5% w/v casein in binding buffer at room temperature for 1 hr. The binding 
and washing buffer consisted of PBS at pH 7.4 with 0.05% v/v Tween 20 (PBS-T) and 0.05% w/v casein as a non-specific blocking agent. 
After washing the wells three times with 200 µl washing buffer, 100 µl β2m (10 µg/ml, 40 µg/ml, or 80 µg/ml) in PBS-T and 0.05% w/v 
casein was added to the wells and incubated for 1 hr at room temperature. For the dose-dependent β2m–collagen I binding curve in Figure S1, 
β2m concentrations of 1 µM, 10.5 µM, 21.6 µM, 33.2 µM, 45.6 µM, 58.6 µM, 72.4 µM, and 91.7 µM were used. After three washes with 200 
µl washing buffer, 100 µl mouse anti-β2m monoclonal antibody (1:2000 v/v in PBS-T and 0.05% w/v casein, Millipore Sigma) was bound to 
β2m in each well by incubating at room temperature for 1 hr. Subsequently, following three washes with 200 µl washing buffer, 100 µl of 
goat HRP-conjugated anti-mouse secondary antibody (1:5000 v/v dilution in PBS-T and 0.05% w/v casein, Genscript) was incubated in the 
wells at room temperature for 30 min. After washing for a final four times with 200 µl washing buffer, the binding of β2m to collagen I was 
detected through a colorimetric assay using a 3,3’,5,5’-tetramethylbenzidine substrate kit (Pierce) according to the manufacturer’s protocol, 
and measuring the absorbance at 450 nm using a Tecan Infinite F50 plate reader with Magellan software.  
ThT fluorescence. 
Amyloid fibril formation was monitored by ThT fluorescence assays of β2m in the presence or absence of collagen I fibrils. Purified 
recombinant β2m lyophilized powder was dissolved in 100 µl of 10 mM sodium phosphate buffer, pH 7.4 or pH 6.2 to 1 mg/ml (85 µM). 
Varying concentrations of collagen I fibrils were separately prepared by incubating collagen I (3.4 mg/ml, 0.34 mg/ml, or 0.17 mg/ml; BD 
Biosciences) in 100 µl PBS, pH 7.4 at 37°C for 1 hr. Each 100 µl fibril suspension was sonicated in a bath sonicator for 10 min and 
centrifuged at 16,500 rpm for 10 min to isolate fibrils. Each collagen I fibril pellet was resuspended in 100 µl of 10 mM sodium phosphate 
buffer, pH 7.4 or pH 6.2 in the presence or absence of 1 mg/ml β2m. Three to six samples were prepared for each condition and were 
transferred to a 96-well plate. ThT was added to each sample to a final concentration of 10 µM. ThT fluorescence was monitored over 650 
hours at 37°C with shaking at 600 rpm in a POLARstar Omega fluorimeter (BMG Labtech). 
NMR. 
For all NMR experiments, purified recombinant [U-
15
N]-labeled β2m was diluted to 300 µM in TBS, pH 7.4 with 0.5 mg/ml casein  and 
10% v/v D2O. Before mixing, collagen I from rat tail tendon was dialyzed against TBS, pH 7.4. The concentration of collagen I after dialysis 
was determined by bicinchoninic acid assay (Pierce). All experiments were performed at 10°C. All data were collected on 700 MHz Bruker 
AVIII or 900 MHz AVI NMR spectrometers equipped with TCI-cryo-probes. Data were processed in NMRPipe
93














N]-labeled β2m were acquired with different concentrations of collagen I (0, 0.12 mg/ml, and 1.2 mg/ml) 





HSQC spectrum of β2m in the presence of collagen I relative to the intensity of the same cross-peak in the absence of collagen I, determined 
in Sparky
94














N spectra using the Carr-
Purcell-Meiboom-Gill (CPMG) pulse sequence
97
 with varying relaxation delays: in the absence of collagen I at 700 MHz- 0, 16, 16, 32, 48, 
64, 64, 80, 96, and 112 ms and 900 MHz- 0, 16, 32, 32, 32, 48, 64, 80, 96, 112, and 128 ms and in the presence of 1.2 mg/ml collagen I at 
700 mHz- 0, 16, 16, 32, 48, 48, 64, and 80 ms and at 900 MHz- 0, 16, 32, 32, 32, 48, 64, 80, and 96 ms. Relaxation delays used to quantify 
15
N-R2 rates of β2m in the presence of 0.6 mg/ml collagen I at 700 MHz were: 0, 8, 8, 16, 24, 32, and 56 ms and in the absence of collagen I: 




 informs on the chemical exchange contribution to R2 by using an in-phase Hahn echo experiment
98
. 
Relaxation delays used in the R2
HE
 experiment both in the presence and absence of 0.6 mg/ml collagen I were: 0.768, 7.68, 7.68, 15.4, 23, 
38.5, and 61.4 ms. In each case, the R2 rates were determined by fitting peak intensities to a single exponential decay function. The chemical 








 was applied to [U-
15





N saturation pulse of 150 or 350 Hz was applied for 0.9 ms at different 
15
N frequency offsets: 0, ±1, ±2, ±4, ±8, ±14, ±21, and ±30 kHz. 
An experiment in which the 
15
N saturation pulse was set to 0 Hz with an offset of 30 kHz was also included as a reference. The 
15
N-DEST 
profiles were extracted for each residue as the peak intensity at each 
15
N saturation offset and were fitted to a two-state model using the destfit 
program
56-57
 by Clore and co-workers to obtain R2
bound
, pbound, and kon
app
. The ΔΘ profile was obtained by measuring Θ for each β2m residue in 
the presence and absence of 0.6 mg/ml collagen I as: 𝛩 =
!!"!"#!!!!"!"# !(!!!"#!!!!!"#)
!!"!"#!!!!"!"#
, and taking ΔΘ = Θ+col – Θ-col. 
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